Additional 150,000 Doses of COVID-19 Oral Antiviral Paxlovid to Be Imported on the 11th

[Image source=Yonhap News]

[Asia Economy Reporter Kim Min-young] The Central Disease Control Headquarters announced on the 10th that an additional 150,000 doses of Pfizer's oral COVID-19 treatment, Paxlovid, will be introduced into the country on the 11th.

Accordingly, the total amount of Paxlovid introduced domestically will be 624,000 doses, combining the existing 474,000 doses with the newly added supply.

As of the 9th, 188,000 doses of Paxlovid have been used domestically, with 286,000 doses remaining.

The total amount of Merck & Company (MSD)'s oral treatment, Lagevrio, introduced is 100,000 doses. As of the 9th, 8,000 doses of Lagevrio have been used, and the remaining stock is 92,000 doses.

The Central Disease Control Headquarters stated, "We will strive to introduce sufficient quantities of oral treatments so that they can be used promptly for patients in need."

This content was produced with the assistance of AI translation services.